Different minor abundance plasma lipids significantly influence thrombin generation in vitro and significant differences in such lipids are linked to risk for venous thrombosis.
| THROMBOSIS, BLOOD COAGULATION AND THROMBIN GENERATION
Thrombotic diseases contribute to morbidity and mortality in deep vein thrombosis and pulmonary embolism (VTE), acute myocardial infarction, and ischemic stroke. VTE in the USA annually results in >500 000 hospitalizations and circa 100 000 deaths. [1] [2] [3] [4] Morbidity and mortality of cardiovascular diseases are often linked to hypercoagulability which is linked to excessive thrombin generation. Both retrospective and prospective studies report associations of initial or recurrent VTE risk with elevated peak thrombin in endogenous thrombin generation (ETP) in vitro assays. [5] [6] [7] [8] [9] [10] Excess amounts of thrombin also contribute to arterial disease. [11] [12] [13] Enhanced thrombin generation in thrombotic diseases may be correlated with other risk factors, such as lipoproteins and lipids.
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Essentials
• Circulating blood contains hundreds of lipids, many of which might influence blood coagulation.
• Recent discoveries about circulating lipids that can affect blood coagulation are reviewed.
• Minor abundance plasma lipids can modulate thrombin generation via direct effects on factor Xa.
• Variations in minor abundance plasma lipids can influence thrombin generation and thrombosis risk.
Thrombin generation is central to regulation of hemostasis and thrombosis and to the pathogenesis of thrombosis. Thrombin, the major product of the blood coagulation pathways (Figure 1 ), involves sequential enzymatic activations of serine protease zymogens enhanced by nonenzymatic cofactors, tissue factor (TF), factors Va and VIIIa. 14, 15 Thrombin is generated by the "prothrombinase" complex (factors Xa:Va:Ca ++ ) which activates prothrombin, and the thrombin can ultimately provide feedback downregulation of its generation through the activated protein C (APC) pathway via thrombomodulin and the endothelial protein C receptor. 16 Canonical prothrombinase components include factors Va and Xa, prothrombin, calcium and magnesium ions and phospholipids. 14, 15 Phosphatidylserine (PS) is a potent prothrombinase lipid cofactor. In purified biochemical systems, model membrane phospholipids (PLs), comprising, in part, PS, bind the gamma-carboxyglutamic acid (Gla) domains of prothrombin and factor Xa and the C1 and C2 domains of factor Va such that multiple PLclotting factor interactions promote and stabilize the prothrombinase complex formation and function. [17] [18] [19] The Gla domain is a common domain in the structures of vitamin K-dependent coagulation factors,
i.e, of prothrombin, factor X, factor IX, factor VII, protein C, and protein S. The Gla domain is located at the N-terminus of the clotting factor and its synthesis involves the unusual post-translational modification of glutamic acid residues by adding an extra carboxyl group to the gamma-carbon of glutamic acid residues. Warfarin blocks the post- Based on the spectrum of lipids in plasma and their multiple activities, blood coagulation and thrombin generation can be physiologically or pathologically directly modulated by plasma lipids (Figure 2A ).
Imbalances of thrombin generation caused by imbalances in plasma lipids may affect hypercoagulability and be associated with thrombosis risk. This review summarizes literature concerning modulation of blood clotting reactions by various minor abundance lipids and their levels in clinical studies of thrombosis patients.
Studies that challenged the widely accepted, simple paradigm for PL-Gla-domain lipid effects on prothrombinase structure and activity involved synthetic, soluble dicaproyl-PS that was reported to promote prothrombinase activity by binding to factor Xa outside the Gladomain ( Figure 2B ). 29, 30 Similarly, recent publications both extend and challenge the simple classical paradigm for PL-Gla-domain-factor Xa interactions because it was shown that several plasma lipids carried by lipoproteins or proteins such as albumin and/or lipid binding proteins (e.g, sphingosine, sphinganine, acyl-carnitines [ACs], and lyso-sulfatide
[LSF]), so called "soluble" lipids, bind factor Xa and alter its procoagulant activity ( Figure 2B ), [31] [32] [33] supporting and extending the challenge of the classical, simple paradigm for lipid-clotting factor interactions.
In summary, innovative findings show that certain, minor abundance plasma lipids can bind directly to factor Xa outside the Gla domain and modulate thrombin generation by the prothrombinase complex ( Figure 2B ), leading to an expanded framework for the paradigm for lipid-clotting factor interactions.
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F I G U R E 1 Blood coagulation and protein C pathways. Thrombin is the major product of the blood coagulation pathways involving sequential enzymatic activations of serine protease zymogens enhanced by nonenzymatic cofactors, factors Va and VIIIa. 14, 15 Thrombin is generated by the "prothrombinase" complex which is formed by binding of factor Xa to factor Va on a phospholipid (PL) surface in the presence of Ca 2+ ions. Small amount of thrombin can be generated by tissue factor with activation of factors VII and X via the extrinsic pathway or following activation of factors XI, VIII, IX, and X via the intrinsic pathway. Once generated, thrombin activates platelets and factor V, factor VIII, and factor XI, thereby stimulating multiple steps in the intrinsic pathway and amplifying thrombin generation. For negative feedback downregulation of thrombin generation, thrombin generates the potent anticoagulant, activated protein C (APC), when it is bound to thrombomodulin (TM) and protein C (PC) is bound to the endothelial protein C receptor (EPCR) 16 Blood coagulation and thrombin generation 
| Plasma sphingolipids, blood coagulation and VTE
Plasma lipoproteins contain sphingolipids as well as phospholipids, [34] [35] [36] and the metabolism of these lipids is notably complex (Figure 3 , Figure   S1 , Table S1 ). Glycolipids play critical roles as bioregulators of a variety of processes such as cell proliferation, cell mobility and apoptosis. 36 Some physiologic sphingolipids were studied for their anticoagulant or procoagulant activities and some common sphingolipids were discovered as potent anticoagulant lipids (see below).
| Sphingolipid metabolism
Sphingolipids are defined by the presence of a long-chain sphingoid backbone (Figure 4) , and the anticoagulant sphingolipids, glucosylceramide (glucocerebroside, GlcCer) and sphingosine, are dynamically metabolized directly from ceramide ( Figure 3 More detailed information including related metabolic enzymes is presented in Figure S1 and Table S2 . *Indicates the effect is on the contact phase; **Indicates the effect is on vWF release. Color highlighting indicates whether a particular lipid inhibits thrombin generation (blue) or enhances thrombin generation (red) or has no effect (green). Square boxes with colored background indicates lipids whose effects on coagulation are discussed in this review. Sph, sphingosine; GlcCer, glucosylceramide; LacCer, lactosylceramide (CD17), GalCer, galactosylceramide; SF, sulfatide; LSF, lyso-sulfatide; SM, sphingomyelin; LSM, lyso-sphingomyelin; Cer, ceramide; sph, sphingosine; sphA, sphinganine; S1P, sphingosine-1-phosphate; 16:0 AC, 16:0 acylcarnitine (palmitoylcarnitine); PC, phosphatidylcholine; PG, phosphatidylglycerol; PA, phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; LPC, lyso-phosphatidylcholine; LPG, lyso-phosphatidylglycerol; LPA, lyso-phosphatidic acid; LPS, lyso-phosphatidylserine; LPE, lysophosphatidylethanolamine; oxPC, oxidized phosphatidylcholine; PEA, palmitoyl-ethanolamide; SEA, stearoyl ethanolamide; AEA, arachidonoyl ethanolamide 
| GlcCer as an anticoagulant
Glycosphingolipids found in plasma include inter alia, the neutral lipids, GlcCer, lactosylceramide (CD17, LacCer), globotriaosylceramide (CD77, Gb3Cer), and globotetraosylceramide (Gb4Cer), 39 as well as various gangliosides (GM3, GD1a, GM2, GT1b, GD1b, GQ1b) and sulfatides. 37, 38 GlcCer contains a hydrophilic glucose moiety that links to the hydroxyl group of ceramide ( Figure 4 ). GlcCer is a key metabolic precursor of several distinct subclasses of glycosphingolipids and is synthesized intracellularly by GlcCer synthase which utilizes UDP-Glc and ceramide as substrates ( Figure 3) . 37, 38 Glycolipids are important components of cell membranes, and glycolipid molecules present their highly varied saccharide residues on cell surfaces as well as on the surface of lipoprotein particles, exposing saccharides in the outer lipid leaflet for interactions with cells, antibodies, bacterial toxins, and viral envelope proteins. 36 GlcCer, LacCer, Gb3Cer, and Gb4Cer have levels of approximately 1-10 μmol/L in plasma, 39 and these glycolipids can contribute to prolongation of plasma clotting times in a similar concentration range as their physiological plasma concentrations. 40 GlcCer exerts substantial anticoagulant activity acting via the protein C pathway as an activated protein C (APC) cofactor in purified protein assays, 40, 41 probably by increasing the affinity of APC for phospholipid vesicles. 42 Other neutral glycolipids (e.g, LacCer and Gb3Cer) also possess anticoagulant activity as APC-cofactors, [40] [41] [42] 
| Lyso-sulfatide as an anticoagulant
Lyso-sulfatide (LSF) ( Figure 4 , Table 1 ) is an anticoagulant plasma lipid. 32 The amount of LSF in HDL was estimated to be 5 μg per mg of HDL. 43 Assuming a HDL concentration of 1 mg/mL, LSF may be present in the lower micromolar range in plasma which is a concentration at which LSF can begin to prolong clotting times (Table 1) . LSF inhibits thrombin generation by prothrombinase in purified reaction mixtures (factor Xa, factor Va, prothrombin and Ca 2+ ) in the presence of PL. 32 LSF also inhibits thrombin generation by prothrombinase when modified factor Xa or modified prothrombin lacking Gla domains (Gla-domainless [des-Gla]-factor Xa or factor Xa/des-Glaprothrombin) are used for purified system assays. 32 Nonetheless, LSF does not inhibit thrombin generation by factor Xa and factor Va in the absence of PLs, 32 a pattern which differs from factor Xa inhibition by sphingosine or long-chain ACs (see below). PLs alter the properties of factor Xa, so a requirement for phospholipid to alter factor Xa activity is not surprising. Surface plasmon resonance binding studies show that LSF binds both to factor Xa and to desGla-factor Xa.
Thus, the binding of LSF to factor Xa which does not require the Gladomain of factor Xa does correlate with inhibition of Gla-domainlessfactor Xa, implying that other domains of factor Xa bind lipids that inhibit its ability to generate thrombin, as also shown for acylcarnitines (see below). As described in the "Thrombosis, Blood Coagulation 
| Sphingosine and its derivatives as anticoagulants
In 1989, sphingosine was reported to decrease thrombin generation by inhibiting the extrinsic pathway of coagulation. 47 Subsequently sphingosine was shown to inhibit specifically factor Xa at notably lower concentrations. 31 Sphingosine and sphinganine, but not ceramide or sphingosine-1-phosphate, potently inhibit thrombin generation in plasma clotting assays when their concentrations are >1.5 μmol/L.
31
When thrombin generation is monitored either in purified reactions mixtures containing factor Xa, factor Va and prothrombin plus other reactants, sphingosine and sphinganine inhibit prothrombin activation. 31 Similarly, in studies using prothrombinase assays, thrombin generation is also inhibited by glucosylsphingosine (lyso-GlcCer), phytosphingosine (plant sphingosine), lyso-sphingomyelin and primary alkylamines (i.e, an amine attached to a fatty acid side chain) with >10 carbons 31 but not by the related sphingolipids, ceramide or sphingosine-1-phosphate. Acylation of the amino group of several of these anticoagulant lipids ablated anticoagulant activity, implicating the need for a positive charge for anticoagulant activity. Binding studies showed that sphingosine binds to fluorescein-labeled factor Xa but not to fluorescein-labeled, Gla-domainless-factor Xa; so sphingosine binding and inhibition require the Gla-domain. Thus, lipid-factor Xa interactions that cause inhibition of thrombin generation differ for the 3 classes of lipids, i.e, sphingosines, LSF, and acylcarnitines. Hence, distinct mechanisms are involved for each class of anticoagulant lipids.
| Clinical association
When the association of VTE with GlcCer and PE levels was studied, VTE was associated with plasma GlcCer deficiency but not with any changes in PE plasma levels. 40 PEA, SEA, AEA 1-6 nmol/L 0.0002 [59] The fluctuations in these lipids which are not mirrored in their circulating plasma levels. Further studies of sphingolipids and thrombotic risk are warranted.
| PLASMA PHOSPHOLIPID DERIVATIVES, BLOOD COAGULATION, AND VTE
| Lyso-phospholipid metabolism
Thrombin generation is classically promoted by phospholipid bilayers or membranes containing PS, and prothrombinase activity may be enhanced by PE when membranes have low levels of PS or cardiolipin. 51, 52 Plasma contains multiple soluble PL derivatives, e.g, lyso-phospholipids (LPLs) and ethanolamides. LPLs are plasma membrane-derived bioactive lipid composed of a single acyl carbon chain attached to a polar headgroup. The acyl moieties of glycerophospholipids are hydorolyzed into LPLs by hydrolytic enzymes such as phospholipase A2 and phospholipase A1. 53 In contrast, the lysophospholipid acyltransferase family is a putative enzyme superfamily which catalyzes the transfer of acyl-CoAs to LPLs to produce different classes of phospholipids. 54 The most abundant LPL is lysophosphatidylcholine (LPC) present at >100 μmol/L, and most plasma LPLs are reversibly associated with albumin or lipoprotein particles. LPC in liposomes was reported to enhance prothrombinase activity, although the potency for this activity is very modest, only two-fold or so. lyso-phosphatidylethanolamine, lyso-phosphatidylglycerol and lysophosphatidylserine. 56 Their plasma levels can reach 1.5, 35, 1.5, and 1.6 μmol/L in acute coronary syndrome patients. 56 The observation that overexpression of Type V soluble phosphodiesterase A2, which produces more lyso-phospholipids, enhances thrombus formation in mice, might suggest the association of LPLs with thrombus formation. 57 Future studies of the effects of various LPLs on thrombin generation and thormbosis are well warranted.
| LPLs as procoagulant plasma lipids
The direct association of soluble LPLs with coagulation reactions has not been extensively studied. As far as we know, only a single study of lyso-phosphatidylserine was reported which showed that this lipid enhances prothrombinase activity. 
| Ethanolamides as procoagulants
An untargeted metabolomic study of subjects taking warfarin led to the surprising discovery that ethanolamides are procoagulant. 59 Ethanolamides are naturally occurring saturated N-acylethanolamines (e.g, PEA in Figure 4 ). N-acyltransferase transfers an acyl group from the sn-1 position of a phospholipid to PE such as PC to form N-acylphosphatidylethanolamine, a precursor of ethanolamides.
Several pathways act upon N-acylphosphatidylethanolamine to produce ethanolamides (Figure 3 , Figure S1 , Table S2 ). [60] [61] [62] Ethanolamide with a longer unsaturated side chain (20:4), arachidonoyl ethanolamide (anandamide, AEA), is one of the most studied ethanolamides as it binds to the cannabinoid receptor. 63 Palmitoyl-ethanolamide (PEA) and stearoyl ethanolamide (SEA), structurally related to AEA, are devoid of affinity for cannabinoid receptors. The role of PEA in inflammation and nociception via a variety of molecular mechanisms has been documented. 64 In coagulation reaction studies, PEA enhanced TF-induced and recalcification-induced thrombin generation in plasma and the enhancement was observed at a concentration as low as 0.17 nmol/L. 59 When the extrinsic pathway was blocked by anti-factor VII antibodies, PEA still enhaced recalcification-induced thrombin generation, suggesting PEA can act on factors outside of the extrinsic pathway of coagulation system. 59 Other mechanistic studies implied that the enhancement of thrombin generation by PEA is dependent of the contact activation. 59 The plasma normal concentrations of PEA, SEA, and AEA are ap- Other ethanolamide analogs, palmitoyl N-isopropylamide and Npalmitoyl taurine, which are lacking a hydroxyl group in the head group showed little enhancement of thrombin generation, suggesting that that the free hydroxyl group in the head group appears to be a key component for the observed procoagulant activity of certain ethanolamides. The levels of certain ethanolamides are decreased in plasma by warfarin, 59 and an anticoagulant consequent effect of warfarin by decreasing the ethanolamides in plasma might be a minor, but potentially additional anticoagulant property of warfarin.
| Soluble dicaproyl-PS as procoagulant
Synthetic, soluble dicaproyl-PS (C6PS) potently promotes prothrombinase activity by binding to factor Xa outside the Gla-domain. 29, 30, 58, 67, 68 Both the C1 and C2 domains of factor Va bind C6PS, and binding to C1 domain can influence prothrombinase complex assembly. 68 C6PS also appears to promote dimer formation of factor Xa and such dimerization may prevent factor Xa binding to factor Va due competition. 69, 70 Furthermore, this short chain lipid binds to factor IXa 71 and protein Z, 72 possibly affecting functions of these molecules. Short chain phospholipids might be produced by oxidation, but this has not been reported to our knowledge; so the pathophysiologic relevance of short chain PLs like C6PS remains unknown.
| Clinical associations
Ovarian cancer patients who exhibit plasma hypercoagulability and elevated VTE risk 73 [76] [77] [78] were used to study VTE and discover novel anticoagulant lipids, as described below.
| Global metabolomics for VTE
Because we had found that certain plasma sphingolipids including glucosylceramide, sphingosine, and LSF are anticoagulant lipids whereas, conversely, some plasma lipids can exert procoagulant properties at physiological levels (see above), we hypothesized that certain soluble plasma lipids or other metabolites that have modest or low abundance might be associated with risk for or protection against VTE. (Figure 4 ), but they belong to the long-chain AC family which plays an important role in energy metabolism through mitochondrial β-oxidation of fatty acids. 87 The acylcarnitines and Co-A are produced by the reaction in which acyl moieties are transferred to carnitine from acyl-CoA by carnitine palmitoyl transferase-I (Figure 3 , Figure S1 , Table S2 ). 87 Once the fatty acid-carnitine is inside the matrix, carnitine palmitoyl transferase -II then converts the long-chain acylcarnitine and CoA back to long-chain acyl-CoA and carnitine ( Figure 3) . 87 Although the physiological regulatory mechanisms of plasma ACs levels are poorly understood, studies using peroxisome proliferator activated receptors agonists, e.g, fibrate, suggest that the β-oxidation enhancement in mitochondria (e.g, increase of carnitine palmitoyl transferase-II activity) promoting catabolism of ACs by peroxisome proliferator activated receptors could be one mechanism to reduce plasma ACs level. 
| Clinical association
Multiple ACs are lower in VTE cases than controls, as noted above. 79 Now there is an obvious need to replicate these findings in different cohorts to establish very firmly the association of lower ACs with VTE risk. Figure S1 , Table S2 ) might act to regulate inflammatory events such as cell proliferation at the same time they act to alter thrombin generation. Notably, a variety of enzymes that regulates lipid metabolism are capable of shifting the balances between sphingosine and ceramide, sphingosine and sphingosine-1-phosphate, glucosylceramide and ceramide, etc. 37, 38 The sphingolipid rheostat which influences the balance between cell survival and cell death might also provide a rheostat for lipids which influence thrombin generation and/or the activity of activated protein C ─ 2 proteins which themselves can influence inflammation, cell survival and apoptosis. 16, 91 Lipid-dependent cross-talk might thus contribute to integrate inflammation and coagulation.
| CONCLUDING REMARKS
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